Optimal sequential enrichment designs for phase II clinical trials.
In the early phase development of molecularly targeted agents (MTAs), a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup, say marker-positive patients, but there is no adequate evidence to show that the MTA does not work for the other s...
| Publicado en: | Statistics in Medicine Vol. 36; no. 1; pp. 54 - 67 |
|---|---|
| Autores principales: | , |
| Formato: | algorithm equations & formulas research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
1/15/2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |